Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $818,818.72. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Wednesday, October 30th, Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.30, for a total value of $57,542.40.
• On Monday, August 26th, Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.22, for a total value of $504,400.00.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $0.11 during midday trading on Friday, reaching $24.47. 618,504 shares of the company's stock were exchanged, compared to its average volume of 860,557. Nurix Therapeutics, Inc. has a 52-week low of $4.96 and a 52-week high of $27.60. The stock has a market capitalization of $1.73 billion, a PE ratio of -8.41 and a beta of 2.20. The business's fifty day moving average price is $24.22 and its two-hundred day moving average price is $20.30.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NRIX has been the topic of a number of research analyst reports. Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They issued an "outperform" rating and a $26.00 target price on the stock. Oppenheimer lifted their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a report on Wednesday, September 4th. Barclays lifted their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the company an "overweight" rating in a report on Monday, July 15th. Stephens reiterated an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, October 14th. Finally, Truist Financial initiated coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They issued a "buy" rating and a $36.00 target price on the stock. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.40.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. J.W. Cole Advisors Inc. bought a new stake in Nurix Therapeutics in the first quarter valued at about $265,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Nurix Therapeutics by 27.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,904 shares of the company's stock valued at $454,000 after buying an additional 6,628 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Nurix Therapeutics by 75.6% in the first quarter. Russell Investments Group Ltd. now owns 53,542 shares of the company's stock valued at $787,000 after buying an additional 23,044 shares during the last quarter. ProShare Advisors LLC increased its holdings in Nurix Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company's stock valued at $176,000 after buying an additional 998 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Nurix Therapeutics by 576.7% in the first quarter. Acadian Asset Management LLC now owns 160,293 shares of the company's stock valued at $2,355,000 after buying an additional 136,606 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.